Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
557 questions in 64 reviews · Effective Practice and Organisation of Care
current versionsNo studies 557 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mobile clinics vs standard static services Resource use · children aged 2 to 6 years with persistent asthma and their caregivers. (Age of participants matches our selection… Mobile clinics for women's and children's health (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Use of health services · adolescents between 12 and 19 years with any chronic condition requiring ongoing clinical care, who are leaving or… Transition of care for adolescents from paediatric services to adult health services (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Disease‐specific outcomes · adolescents between 12 and 19 years with any chronic condition requiring ongoing clinical care, who are leaving or… Transition of care for adolescents from paediatric services to adult health services (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Well‐being measures · adolescents between 12 and 19 years with any chronic condition requiring ongoing clinical care, who are leaving or… Transition of care for adolescents from paediatric services to adult health services (2016) · Cochrane | no estimate extracted | NR | No studies |
Integrated management of childhood illness strategy vs routine care Satisfaction of beneficiaries · children < 5 years of age Integrated management of childhood illness (IMCI) strategy for children under five (2016) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare outcomes · healthcare professionals Tailored interventions to address determinants of practice (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs · healthcare professionals Tailored interventions to address determinants of practice (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse effects · healthcare professionals Tailored interventions to address determinants of practice (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Distant consultancy · patients needing elective specialist ambulatory visit or surgery Interventions to reduce waiting times for elective procedures (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Generic waiting list · patients needing elective specialist ambulatory visit or surgery Interventions to reduce waiting times for elective procedures (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR BCMA vs no BCMA Interventions for reducing medication errors in children in hospital (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR aPrescriptions. Interventions for reducing medication errors in children in hospital (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CPOE vs no CPOE Interventions for reducing medication errors in children in hospital (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation Pharmaceutical policies: effects of financial incentives for prescribers (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes Pharmaceutical policies: effects of financial incentives for prescribers (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Costs Pharmaceutical policies: effects of financial incentives for prescribers (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable population: senior 65 years of age or older Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Emergency department and hospitalisation · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Outpatient care · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcome · seniors and general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Use of medicines for asymptomatic conditions · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on medicines) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Insurer perspective (expenditures on health care) · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall healthcare utilisation · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · vulnerable and general populations Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Health outcomes · vulnerable population (retirees and low income) Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Medicine use · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Cost · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Patient perspective · low‐income/general population Pharmaceutical policies: effects of cap and co‐payment on rational use of medicines (2015) · Cochrane | no estimate extracted | NR | No studies |